Abstract 248P
Background
Cyclic fasting or fasting-mimicking diets (FMDs) enhanced the antitumor activity of chemotherapy (CT) in TNBC mouse models, while the combination of fasting and metformin resulted in impressive antitumor activity in several preclinical tumor models. The BREAKFAST study was designed to investigate if cyclic FMD, plus/minus metformin, improves the antitumor activity of neoadjuvant CT in patients (pts) with localized TNBC.
Methods
BREAKFAST is a randomized, non-comparative, phase II trial originally designed to enrol 90 stage I-III (cT>1cm) TNBC pts candidate to receive neoadjuvant doxorubicin-cyclophosphamide q3w for 4 cycles, followed by weekly paclitaxel for 12 cycles. Pts were randomized 1:1 to receive: CT + triweekly 5-day FMD cycles (arm A), or CT + FMD + daily metformin (1700 mg) (arm B). The primary study objective was to investigate if one or both experimental treatments were able to increase pCR rates when compared to anthracycline-taxane CT alone according to historical data.
Results
We enrolled 30 pts between June 2020 and February 2022, when the study was prematurely interrupted after the introduction of chemo-immunotherapy (CT-IO) as a standard neoadjuvant therapy for early stage TNBC. Of these pts, 13 were randomized to arm A and 17 to arm B; 73.3% of enrolled pts completed the maximum of 8 FMD cycles, with an average number of 6.9 completed FMD cycles. The observed pCR rate was 56.6%, i.e., significantly higher than pCR rates previously reported with CT alone in phase II/III trials (26-39%), and with no significant differences among treatment arms (OR 1.67, 95% CI 0.39-7.43; p=0.49). RNA-seq analysis in tumor specimens revealed higher pCR probability in pts undergoing precocious enhancement of tumor infiltration by activated T and NK cells, as well as precocious downmodulation of glycolysis and oxidative mitochondrial metabolism pathways.
Conclusions
Preoperative CT plus cyclic FMD (plus/minus metformin) results in excellent pCR rates in early TNBC pts. Based on these findings, we recently initiated a phase II, randomized, multicentric trial, namely BREAKFAST-2, to investigate if adding cyclic FMD to neoadjuvant CT-IO increases pCR rates in stage II-III TNBC pts.
Clinical trial identification
NCT04248998.
Editorial acknowledgement
Legal entity responsible for the study
Fondazione IRCCS Istituto Nazionale dei Tumori.
Funding
Fondazione IRCSS Istituto Nazionale dei Tumori; AIRC.
Disclosure
F. Ligorio: Financial Interests, Personal, Other, Travel/accomodation: Eli Lilly, Istituto Gentili; Financial Interests, Personal, Invited Speaker: Novartis. R. Lobefaro: Financial Interests, Personal, Advisory Board: Daiichi Sankyo, AstraZeneca; Financial Interests, Personal, Speaker, Consultant, Advisor: Pfizer; Financial Interests, Personal, Other, Travel/accomodation: Eli Lilly. G.V. Bianchi: Financial Interests, Personal, Advisory Board: Novartis, Eli Lilly, Daiichi Sankyo, AstraZeneca, Roche, MSD, Seagen. G. Pruneri: Financial Interests, Personal, Advisory Role: Roche, Bayer; Financial Interests, Personal, Advisory Board: AstraZeneca. F.G.M. De Braud: Financial Interests, Personal, Advisory Board: Roche, EMD Serono, NMS Nerviano Medica Science, Sanofi, MSD, Novartis, Incyte, BMS, Menarini, AstraZeneca, Pierre Fabre, Mattioli 1885 , MCCann Health, Taiho, IQVIA; Financial Interests, Personal, Speaker’s Bureau: BMS, Healthcare Research & Parmacoepidemiology, Merck Group, MSD, Pfizer, Servier, Sanofi, Roche, AMGEN, Incyte, Dephaforum, Seagen, Nadirex, Ambrosetti, Itanet; Financial Interests, Personal and Institutional, Sponsor/Funding: Novartis, F.Hoffmann-LaRoche Ltd, BMS, Ignyta Operating INC, Merck Sharp & Dohme Spa, Kymab, Pfizer, Tesaro, MSD, MedImmune LCC, Exelixis Inc., LOXO Oncology Incorporated, Daiichi Sankyo, Basilea Pharmaceutica International AG, Janssen-Cilag Internationa NV, Merck KGAA. C. Vernieri: Financial Interests, Personal, Advisory Board: Novartis, Pfizer, Lilly, Daiichi Sankyo, Novartis, Lilly, Istituto Gentili; Financial Interests, Institutional, Research Grant: Roche. All other authors have declared no conflicts of interest.
Resources from the same session
253P - Is 6-weekly administration of pembrolizumab in combination with chemotherapy for early triple-negative breast cancer safe? A real-world early comparison of q6w versus q3w administration of pembrolizumab in two large cancer centres in the UK
Presenter: Vasileios Angelis
Session: Poster session 02
254P - Effects of delaying adjuvant chemotherapy initiation on clinical outcomes in early triple-negative breast cancer patients
Presenter: Maria Eleni Hatzipanagiotou
Session: Poster session 02
255P - Prognostic stratification capacity of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy
Presenter: Nicolas Roussot
Session: Poster session 02
256P - Evolution and risk stratification of adjuvant treatment strategies for early breast cancer: A Chinese perspective based on a national cancer database
Presenter: Ying Fan
Session: Poster session 02
257P - The characteristics of HER2-positive microinvasive breast cancer and the necessity of chemotherapy and anti-HER2 therapy in these patients: A real-world study
Presenter: Bo Lan
Session: Poster session 02
258P - Cost-effectiveness of neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab for high-risk early-stage triple-negative breast cancer in Colombia
Presenter: Ricardo Brugés Maya
Session: Poster session 02
259P - Adjuvant doxorubicin-cyclophosphamide in early-stage breast cancer provides long-term cardiac safety
Presenter: Thiti Susiriwatananont
Session: Poster session 02
260P - Oncology efficacy of gonadotropin-releasing hormone agonist in hormone receptor-positive very young breast cancer patients treated with neoadjuvant chemotherapy
Presenter: Hee Jun Choi
Session: Poster session 02
261P - Dysregulation of immune checkpoint proteins in newly- diagnosed early breast cancer patients undergoing neoadjuvant chemotherapy: A comparison between TNBC and non-TNBC patients
Presenter: Bernardo Rapoport
Session: Poster session 02